Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia

Lipid Research Clinics Program, 1984, The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025 Brensike, 1984, Effects of therapy with cholestyramine on progression of coronary arteriosclerosis:results of the NHLBI Type II Coronary Intervention Study, Circulation, 62, 313, 10.1161/01.CIR.69.2.313 Levy, 1973, Cholestyramine in type II hyperlipoproteinemia. A double-blind trial, Ann Intern Med, 72, 51, 10.7326/0003-4819-79-1-51 Sheperd, 1989, Mechanism of action of bile acid sequestrants and other lipidlowering drugs, Cardiology, 76, 65, 10.1159/000174548 Goldfarb, 1972, Stimulatory effects of dietary lipid and cholestyramine on hepatic HMG CoA reductase, J Lipid Res, 13, 797, 10.1016/S0022-2275(20)39351-2 Blum, 1989, Current therapy for hypercholesterolemia, JAMA, 261, 3582, 10.1001/jama.1989.03420240096034 Bressler, 1966, Treatment of hypercholesterolemia and hypertriglyceridemia by anion exchange resin, South Med J, 59, 1097, 10.1097/00007611-196609000-00022 Howard, 1970, Effect of cholestyramine administration on serum lipids and on nitrogen balance in familial hypercholesterolemia, J Lab Clin Med, 68, 12 National, 1988, Arch Intern Med, 148, 36, 10.1001/archinte.1988.00380010040006 Moore, 1968, Effect of cholestyramine on fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in the hypercholesterol patient, J Clin Invest, 47, 1664, 10.1172/JCI105857 Series, 1989, Effect of combined therapy with a bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia, Metabolism, 38, 153, 10.1016/0026-0495(89)90255-2 LaRosa, 1989, Review of clinical studies of bile acid sequestrants for lowering plasma levels, Cardiology, 76, 5 Crouse, 1987, Hypertriglyceridemia:a contraindication to the use of bile acid binding resins, Am J Med, 83, 243, 10.1016/0002-9343(87)90692-9 Denke, 1988, Hypertriglyceridemia:a relative contraindication to the use of bile-acid binding resins?, Hepatology, 8, 974, 10.1002/hep.1840080446 Lipid Research Clinics Program, 1984, The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering, JAMA, 251, 365, 10.1001/jama.1984.03340270043026 Levy, 1984, The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease:results of the NHLBI Type II Coronary Intervention Study, Circulation, 69, 325, 10.1161/01.CIR.69.2.325 Kuo, 1979, Use of a combined diet and colestipol in long term (7 to 7 1/2 years) treatment of patients with type II hyperlipoproteinemia, Circulation, 59, 199, 10.1161/01.CIR.59.2.199 Blankenhorn, 1987, Beneficial effects of colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts, JAMA, 257, 3233, 10.1001/jama.1987.03390230069027 Ost, 1967, Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid, Scand J Clin Lab Invest, 19, 241 Nash, 1982, Effect of lipid-lowering therapy on progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography, Int J Cardiol, 2, 43, 10.1016/0167-5273(82)90008-0 Duffield, 1983, Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis:a randomised controlled trial, Lancet, 2, 639, 10.1016/S0140-6736(83)92527-8